Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 2/20 | 0.42 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.38 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | DUT | P33316 | 3/20 | 0.37 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.37 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | POLA1 | P09884 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5978909 | 0.99 | TYMP (0.42) | TYMPP2RY2P2RY4CYP3A4CYP2C9 | |
| SCHEMBL5978913 | 0.87 | P2RY2 (0.36) | P2RY2P2RY4CYP3A4CYP2C9DUT | |
| SCHEMBL31467681 | 0.84 | CYP3A4 (0.41) | TYMPP2RY2P2RY4CYP3A4CYP2C9 | |
| SCHEMBL13575501 | 0.84 | P2RY2 (0.54) | TYMPP2RY2P2RY4CYP3A4CYP2C9 | |
| SCHEMBL21905172 | 0.83 | TYMP (0.45) | TYMPP2RY2P2RY4CYP3A4CYP2C9 | |
| SCHEMBL13837115 | 0.83 | TYMP (0.45) | TYMPP2RY2P2RY4CYP3A4CYP2C9 | |
| SCHEMBL31467672 | 0.83 | TYMP (0.45) | TYMPP2RY2P2RY4CYP3A4CYP2C9 | |
| SCHEMBL5977396 | 0.82 | TYMP (0.47) | TYMPP2RY2P2RY4P2RY14 | |
| SCHEMBL19185368 | 0.82 | CYP3A4 (0.52) | TYMPP2RY2P2RY4CYP3A4CYP2C9 | |
| SCHEMBL12701331 | 0.82 | TYMP (0.45) | TYMPP2RY2P2RY4CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171048-A1 | Nuclease activity resistance; mixed sequence oligonucleotides containing purine or pyrimidine base in beta anomeric configuration; drug delivery agents; targeting specific DNA and/or RNA sequences | ISIS PHARMACEUTICALS, INC. (US) | 2005-08-04 | — | — | US | disclosed |
| US-6911540-B2 | 2′ Modified oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2005-06-28 | — | — | US | disclosed |
| EP-0942000-B1 | 2'-Modified oligonucleotides | ISIS PHARMACEUTICALS INC (US) | 2004-06-23 | — | — | EP | disclosed |
| US-20030036649-A1 | 2' modified oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2003-02-20 | — | — | US | disclosed |
| US-6476205-B1 | 2′ Modified oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2002-11-05 | — | — | US | disclosed |
| EP-0497875-B1 | 2' MODIFIED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 2000-03-22 | — | — | EP | disclosed |
| EP-0942000-A2 | 2'Modified oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 1999-09-15 | — | — | EP | disclosed |
| US-5792847-A | ANTISENSE AGENTS, ANTISENSE THERAPY; ANTITUMOR AGENTS | GILEAD SCIENCES, INC. (US) | 1998-08-11 | — | — | US | disclosed |
| US-5466786-A | Drug delivery | GILEAD SCIENCES (US) | 1995-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030036649-A1 | 2' modified oligonucleotides | DCLRE1B, POLRMT, POLM | TYMP 10/4885P2RY2 2304/4885P2RY4 3600/4885 |
| US-20050171048-A1 | Nuclease activity resistance; mixed sequence oligonucleotides containing purine or pyrimidine base in beta anomeric configuration; drug delivery agents; targeting specific DNA and/or RNA sequences | ADAR, POLM, POLRMT | TYMP 14/4885P2RY2 587/4885P2RY4 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.